ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 74

LILRA3 Promotes Lupus-like Chronic Graft-versus-Host Disease by Expansion of Follicular Helper T Cells and Anti-dsDNA Autoantibodies

Yundi Tang1, Yuxuan Wang 1, Yundong Zou 1, Mengru Liu 1, Yan Du 1 and Jianping Guo 1, 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cellular response and autoantibody production, knock-in mice, LILRA3, lupus-like disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Animal Models Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a soluble member of LILR family. We previously reported that LILRA3 is a novel genetic risk for multiple autoimmune diseases, including systemic lupus erythematosus (SLE). However, it is unclear how LILRA3 contributes to the pathogenesis of SLE. This study was undertaken to examine the in vivo role of LILRA3 and its possible mechanism(s) in development of lupus in a chronic graft-versus-host disease (cGVHD) model.

Methods: To functionally study the role of LILRA3 in lupus pathogenesis, we generated a novel LILRA3 knock-in (LILRA3-KI) mouse and evaluated clinical and immunological phenotypes in the bm12-induced cGVHD model. Human LILRA3 gene (Gene ID: 11026) was inserted into Rosa26 allele in C57BL/6 (B6) mice based on Cas9/sgRNA system. The cGVHD was induced by an intraperitoneal injection of the bm12 donor splenocytes into recipients, either B6 wild-type (B6-WT) or LILRA3-KI mice. Mice were assessed for the development of splenomegaly, immune cellular response, autoantibody production, and renal pathology.

Results: Compared with B6-WT recipient mice, the LILRA3-KI mice displayed a more pronounced lupus-like phenotype and immune response, which includes an apparent spleen enlargement (p < 0.001); expansion of Tfh cells (p < 0.001), germinal center (GC) B cells (p < 0.01), and plasma B cells (p < 0.001); and elevated levels of serum anti-double-stranded DNA IgG autoantibodies (p < 0.001).

Conclusion: Our data indicate that LILRA3 promotes lupus-like disease probably through the excessive expansion of Tfh, GC B, and plasma cells, and subsequently leading to an excessive production of anti-dsDNA autoantibodies.

Figure 1. Construction strategy of the LILRA3 knock-in mice. Humanized LILRA3 knock-in -LILRA3-KI- mice were constructed on C57BL/6 background. A full-length sequence of human LILRA3 gene -Gene ID: 11026- was inserted into the C57BL/6 Rosa26 allele based on CRISPR-Cas9 technology -A-. LILRA3 expression was confirmed by southern blot -B-, PCR -C-, and ELISA -D-. After cGVHD, serum LILRA3 was highly expressed in bm12→KI mice at both days 14 and 28 -E-. The bm12→KI mice showed a significant aggravation of splenomegaly -F-. Results from F: data were obtained from 2 independent experiments at day 14 -B6→B6: n=9; bm12→B6: n=12; bm12→KI: n=12-. At day 28, data were obtained from a single experiment -B6→B6: n=4; bm12→B6: n=6; bm12→KI: n=4-. Data are displayed as mean±SD. ** p < 0.01, *** p < 0.001.

Figure 2. Increased expansion of Tfh cells in LILRA3-KI cGVHD mice. On days 14 and 18, the frequencies of CD4+IFNγ+ Th1 cells -A-, CD4+IL-17A+ Th17 cells -B-, CD4+CD25+FoxP3+ Tregs -C-, and CD4+PD-1+CXCR5+ Tfh cells -D- from splenocytes were determined by flow cytometry. At day 14, data were obtained from 2 independent experiments -B6→B6: n=9; bm12→B6: n=12; bm12→KI: n=12-. At day 28, data were obtained from a single experiment -B6→B6: n=4; bm12→B6: n=6; bm12→KI: n=4-. Data are displayed as mean±SD. * p < 0.05, ** p < 0.01, *** p < 0.001.

Figure 3. Increased expansion of GC B, plasma cells and anti-dsDNA autoantibody production in LILRA3-KI cGVHD mice. On days 14 and 18, the frequencies of CD19+FAS+GL-7+ GC B cells -A-, and CD19+CD138+B220- plasma cells -B- from splenocytes were determined by flow cytometry. Serum levels of anti-dsDNA IgG -C-, and ANA -D- were measured by ELISA. At day 14, data were obtained from 2 independent experiments -B6→B6: n=9; bm12→B6: n=12; bm12→KI: n=12-. At day 28, data were obtained from a single experiment -B6→B6: n=4; bm12→B6: n=6; bm12→KI: n=4-. Data are displayed as mean±SD. ** p < 0.01, *** p < 0.001.


Disclosure: Y. Tang, None; Y. Wang, None; Y. Zou, None; M. Liu, None; Y. Du, None; J. Guo, None.

To cite this abstract in AMA style:

Tang Y, Wang Y, Zou Y, Liu M, Du Y, Guo J. LILRA3 Promotes Lupus-like Chronic Graft-versus-Host Disease by Expansion of Follicular Helper T Cells and Anti-dsDNA Autoantibodies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/lilra3-promotes-lupus-like-chronic-graft-versus-host-disease-by-expansion-of-follicular-helper-t-cells-and-anti-dsdna-autoantibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lilra3-promotes-lupus-like-chronic-graft-versus-host-disease-by-expansion-of-follicular-helper-t-cells-and-anti-dsdna-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology